Minichromosomal maintenance protein 7 (MCM7) is an essential component of the replication helicase complex (MCM2-7) required for DNA replication. Although this function is highly conserved among eukaryotes, additional functions for the MCM molecules continue to be described. Minichromosomal maintenance protein 7 is a marker for proliferation and is upregulated in a variety of tumors including neuroblastoma, prostate, cervical and hypopharyngeal carcinomas. To further investigate the general role of MCM7 in tumorigenesis, we generated a mouse model with deregulated MCM7 expression targeted to the basal layer of the epidermis using the keratin 14 (K14) promoter (K14.MCM7). When subjected to a two-stage chemical carcinogenesis protocol (dimethylbenz[a]anthracene (DMBA) initiation with 12-ortho-tetradecanoylphorbol-13-acetate promotion), K14.MCM7 mice showed significantly increased incidence and prevalence of tumor development relative to controls. Furthermore, within 40 weeks of treatment over 45% K14.MCM7 mice exhibited tumors that had converted to squamous cell carcinomas versus none in the control group. As predicted from previous skin carcinogenesis studies using DMBA as the initiating agent, Ras mutations where found in more than 90% of tumors isolated from K14.MCM7 mice. Whereas previous studies have shown that MCM7 is useful as a proliferation marker, our data suggest that deregulated MCM7 expression actively contributes to tumor formation, progression and malignant conversion.
Introduction
Minichromosomal maintenance proteins (MCMs) were initially identified in yeast and subsequently shown to be expressed in all eukaryotic organisms (Tye, 1999) . Minichromosomal maintenance protein 7 is part of a DNA binding heterohexamer complex (MCM2-7). The essential DNA replication initiation function and associated DNA helicase activities of the MCM complex have been extensively reviewed (Homesley et al., 2000; Pasion and Forsburg, 2001) . Individual MCM proteins also help to regulate transcription, chromatin remodeling and check point responses (see Forsburg, 2004 and references therein) . Recent studies suggest that MCM proteins are involved in modulating E2F-driven transcriptional regulation (Tye and Chang, 2004) . Evidence for additional functions for MCM7 is partly derived from biochemical and in vitro observations that MCM7 interacts with several proteins involved in regulation of cell cycle progression and proliferation including Rb (Sterner et al., 1998) , Mat-1 , FLH (Chan et al., 2000) , and HPV-E6 (Kukimoto et al., 1998) . We describe herein an additional role of MCM7 contributing to the process of chemical carcinogenesis as assessed in an in vivo transgenic model.
As MCM proteins are involved in multiple cellular functions in addition to regulation of DNA synthesis and transcription, they may contribute to tumorigenesis. In fact, MCM 2, 5, and 7 have been described as potential biomarkers in human cervical cancers (Freeman et al., 1999) . However, so far only MCM7 has been reported to be highly expressed in the more aggressive (CIN III) as compared to the less aggressive (CIN II) high grade dysplasia in the cervix (Brake et al., 2003) , whereas no differences in MCM2 or MCM5 could be found in CIN II and CIN III lesions. Additional studies have recently demonstrated that elevated MCM7 expression levels correlate with aggressive prostate cancer (Padmanabhan et al., 2004) and head and neck squamous cell carcinomas (HNSCC) (Cromer et al., 2004) . Notably, MCM7 is the only MCM family member whose promoter contains an E-box sequence, which is the binding site for members of the MYC transcription factor family (Eisenman, 2001 ). Recent studies have revealed that MCM7 is a direct target of both the MYCC (Fernandez et al., 2003) and MYCN (Shohet et al., 2002) oncoproteins. Furthermore, high MCM7 protein levels are closely correlated with MYCN amplification in high stage neuroblastoma tumors (Shohet et al., 2002) .
The hypothesis that MCM7 has an active role in tumorigenesis derives from the observations that MCM7 is expressed at high levels in multiple malignancies and that MCM7 interacts with numerous proteins involved in cellular proliferation. To explore this possibility, we generated transgenic mice with deregulated MCM7 expression targeted to the basal layer of the epidermis (keratin 14 (K14).MCM7) and subjected these mice to chemical carcinogenesis. We discovered that K14.MCM7 mice developed skin papillomas at a faster rate than control mice in response to a two-step carcinogenesis protocol. In addition, K14.MCM7 tumors had a much higher rate of conversion to SCC compared to control tumors, suggesting that MCM7 cooperates with oncogenic Ras in skin tumorigenesis.
Results
To determine if elevated MCM7 levels contribute to tumorigenesis, we generated a transgenic mouse model in which MCM7 was targeted to the epidermis and hair follicles using a K14 promoter (K14.MCM7) (Figure 1a ). The K14 promoter is not only expressed in keratinocytes in the basal layer of the epidermis, the outer root sheath of the hair follicle and the sebaceous gland, but also in epidermal stem cells and multipotent stem cells that reside in the bulge region of the hair follicle (Berton et al., 2000; Arin et al., 2001; Cao et al., 2001; Waikel et al., 2001) . Three founder lines with a C57/BL6 genetic background were established, each exhibiting a different level of MCM7 transgene expression. The highest expressing line was used for this study. Presence of the transgene was confirmed by genomic PCR using primers that recognize the b-globin intron and the MCM7 coding sequence. Utilizing primers specific for the human gene, we detected MCM7 transgene expression by RT-PCR in RNA samples isolated from skin before treatment and in all tumors from the K-14.MCM7 mice ( Figure 1b) . As expected no human MCM7 mRNA could be detected in the wildtype littermate controls. Histological analysis of whole skin samples from both transgenic and control mice showed no differences in overall morphology (data not shown). However, immunohistochemistry with an antibody crossreactive to both the mouse and human MCM7 protein clearly demonstrated increased MCM7 protein in the basal layer of the epidermis and the outer root sheath of the hair follicle, cells targeted by the K14 promoter ( Figure 1c) .
To determine if MCM7 plays a role in tumorigenesis, we subjected K14.MCM7 and wild-type littermates to a two-stage chemical skin carcinogenesis protocol. Skin cancer, like most cancers, is a multistage process that arises due to an accumulation of discrete genetic changes. This process can be recapitulated in mice using a two-stage chemical carcinogenesis protocol that Figure 1 MCM7 transgene expression. Elevated expression of the human MCM7 can be detected in the basal layer of the epidermis and hair follicles in K14.MCM7 samples compared to wild-type littermate samples taken on P2. (a) Full-length human MCM7 cDNA was cloned into the K14 promoter intron construct and the linearized transgene fragment was injected into fertilized oocytes as previously described (Waikel et al., 1999) . (b) Transgene expression was confirmed in K14.MCM7 untreated whole skin and K14.MCM7 tumors by RT-PCR using gapdh as a positive template control. Primers were specific for the human MCM7 gene.
(SCC ¼ squamous cell carcinoma, Pap ¼ papilloma, SH ¼ sebaceous hyperplasia and Wt ¼ wild type) (c) Comparative MCM7 immunohistochemistry demonstrates markedly elevated MCM7 expression in K14.MCM7 transgenic mice compared to wild-type littermates. Measure bar equals 100 mm.
involves an initiation and a promotion phase (DiGiovanni, 1992) . The initiation phase is achieved by treatment with a single subcarcinogenic dose of a skin carcinogen, such as dimethylbenz[a]anthracene (DMBA), which causes irreversible DNA damage but does not lead to tumor development alone. Dimethylbenz[a]anthracene treatment results in the formation of DNA adducts, which frequently result in mutational activation of Ras proto-oncogenes. In fact, nearly 95% of carcinomas that develop in response to using DMBA as an initiator exhibit Ras mutations (Bremner et al., 1994) . Repeated exposure to a tumor promoter, such as 12-ortho-tetradecanoylphorbol-13-acetate (TPA), results in clonal expansion of initiated cells and tumor formation. Once tumors develop, the conversion of papillomas to squamous cell carcinoma (SCC) marks the progression phase of the two-stage carcinogenesis protocol. As tumor promotion can result in tumor formation long after an initiation event, it is presumed that stem cells are the targets of initiation (Yuspa and Poirier, 1988) .
To initiate the two-stage chemical carcinogenesis protocol, three week-old K14.MCM7 littermates were treated once with DMBA. Promotion started 1 week later with weekly treatments of TPA. Mice were monitored for tumor formation and conversion from papillomas to SCC for a total of 52 weeks. Untreated K14.MCM7 or wild-type control mice did not develop spontaneous tumors after 1 year. However, following exposure to DMBA/TPA, K14.MCM7 mice exhibited a marked increase in susceptibility to chemical carcinogenesis as compared to wild-type littermates. Histologic evaluation of the resultant tumors displayed the expected histology of papilloma and SCC formation (Figure 2a) . The SCCs that developed in K14.MCM7 mice were moderately differentiated and there was little difference of tumor histology between littermates. Notably, K14.MCM7 mice also developed sebaceous gland hyperplasia (Figure 2a) . We performed MCM7 immunostaining on skin, papillomas and carcinomas arising from both the transgenic and control animals subjected to identical carcinogenesis protocols. Minichromosomal maintenance protein 7 expression levels were qualitatively similar between both groups of mice (antibody detects both mouse and human MCM7) as shown in Figure 2b . The primary difference is the level of MCM7 at baseline before treatment. These findings support our hypothesis that elevated MCM7 accelerates tumorigenesis and likely sensitizes normal epithelium to the effects of DMBA and TPA.
K14.MCM7 mice started developing tumors 13 weeks after initiation, while wild-type mice did not start developing tumors until 20 weeks after initiation (Figure 3 ). Transgenic mice developed more tumors per mice and by 43 weeks of treatment, the K14.MCM7 mice had on average three tumors each whereas the controls had less than one tumor/mouse (Po0.001) (Figure 3a) . By 25 weeks after initiation, 13 (65%) mice of K14.MCM7 mice had developed tumors, as compared to only two (10%) wild-type mice (Figure 3b ). .MCM7 mice developed papillomas, squamous cell carcinomas (SCC) and sebaceous gland hyperplasia as shown by H&E staining. The resultant sebaceous gland hyperplasia was marked with an increase in sebaceous glands that lacked atypical or dysplastic features. Squamous papillomas were found raised from the surrounding skin surface and lined by squamous epithelial cells with hyperplasia, but lacked atypical or dysplastic changes. Squamous cell carcinomas were identified in samples with apparent malignant epithelial cells that invaded the underlying dermis and were well-tomoderately differentiated with some SCCs containing keratinized cells and keratin pearls and some containing occasional keratinized cells with no keratin pearls. (b) MCM7 expression appears similar between papillomas and carcinomas arising from transgenic and wild-type animals. The primary difference noted is in the initial level of MCM7 seen in the skin before and after treatment. Once tumors form, MCM7 levels increase in the rapidly dividing nontransgenic cells consistent with proliferation-dependent upregulation of MCM7.
After 42 weeks, 80% of K14.MCM7 mice developed tumors as compared to 35% of wild-type mice (Po0.03). These data clearly demonstrate both more rapid and more prevalent induction of tumors in the MCM7 transgenic animals.
K14.MCM7 mice also exhibited a dramatic increase in conversion of papillomas to SCCs as compared to control mice. Of 20 K14.MCM7 mice, 10 (50%) had developed SCCs by 40 weeks following initiation whereas none had developed in wild-type mice (Po0.001) (Figure 4 ). Only one mouse in the control group (5%) developed SCC by the end of the observation period whereas K14.MCM7 mice with SCC all had multiple tumors converted. These data demonstrate that deregulated MCM7 expression in the epidermis strongly influences both the incidence and prevalence of papilloma formation as well as the conversion from papilloma to SCC in the chemical carcinogenesis model.
Activating point mutations in members of the Ras proto-oncogene family (K-Ras and H-Ras) are well known to be associated with the initiation of transformation in the two-stage chemical carcinogenesis model (Barrett and Anderson, 1993) . These mutations lead to deregulated growth and proliferation, are usually clustered in exons 1 and 2 of the Ras genes, and most frequently are found at codons 12, 13, 59 and 61 of HRas and K-Ras (Nelson et al., 1992; Barrett and Anderson, 1993) . We therefore performed sequence analysis of the characterized mutational hot spot regions within K-Ras and H-Ras genes in tumors that developed in K14.MCM7 mice. Nine out of nine tumors (from six different mice showed H-Ras mutations of codon 59 (Thr-Ala) and no significant mutation of the K-Ras gene was found. These data demonstrate the expected high Ras mutation rate indicative of DMBA initiation found in other skin cancer model systems and suggest that MCM7 cooperates with Ras in tumorigenesis.
To assess whether deregulated MCM7 expression alters genomic instability, we evaluated tumor ploidy using flow cytometry on paraffin-embedded tumor specimens. Of the seven tumors analysed (six papillomas, one SCC), the histogram of one papilloma displayed a separate aneuploid peak (data not shown). No evidence for aneuploidy was observed in the remaining six tumors. Although this data suggests that elevated MCM7 levels do not alter the incidence of large-scale genomic instability, the possibility that it contributes to this process during later tumor progression cannot be excluded.
Discussion
In our mouse model, targeted overexpression of MCM7 in epithelial progenitor cells leads to statistically significant increases in tumor formation and malignant conversion upon carcinogen exposure. This represents an in vivo confirmation of our hypotheses that altered MCM7 levels predispose cells to transformation.
The long latency period before tumor formation and conversion is due to the C57BL/6 genetic background of the K14.MCM7 mice. This background is highly resistant to two-stage carcinogenesis (Ashman et al., 1982; DiGiovanni et al., 1987; Woodworth et al., 2004) . Mice with the C57BL/6 genetic background, treated with similar doses of DMBA and TPA as our K14.MCM7, mice develop only 0.2 papillomas per mouse after 44 weeks of treatment (Woodworth, 2004) . Furthermore, keratinocytes isolated from C57BL/6 mice and subjected to conversion assay resulted in no conversion. These data suggest that the C57BL/6 genetic background is highly resistant to both tumor development and conversion in response to chemical carcinogenesis. Our results indicate that deregulated MCM7 expression can override this genetic resistance of C57BL/6 mice.
Elevated MCM7 expression has been reported in prostate (Padmanabhan et al., 2004) , cervical (Brake et al., 2003) , head and neck (Cromer et al., 2004) and pancreatic cancers (Grutzmann et al., 2004) . In neuroblastoma, MCM7 is transcriptionally regulated by MYCN and increased expression was found to correlate with aggressive MYCN amplified tumors (Shohet et al., 2002) . Most recently, in prostate tumors, MCM7 gene amplification was found in a high proportion of specimens and overexpression strongly correlated with a more aggressive phenotype and progressive disease (Ren et al., 2005) . Clarification of the role that MCM7 plays in the pathogenesis of these tumors will require additional investigations characterizing the molecular interactions of MCM7 and the identification of protumorigenic cellular pathways influenced by elevated MCM7 protein levels.
The K14.MCM7 mouse model is the first to explore a role for MCM7 in in vivo tumor formation. Our results indicate that, aside from its function as part of the DNA replication licensing factor, MCM7 may participate in the process of tumorigenesis, contributing to Ras initiated tumorigenesis of epidermal skin cells. These results are further supported by the observation that overexpression of MCM7 in human colon cells induced the acceleration of tumor formation, but had no effect on the activity of cellular DNA replication (Yoshida and Inoue, 2003) .
Earlier reports suggested that MCM molecules are useful markers of proliferation as they are E2F-regulated genes and are required for DNA synthesis (Wharton et al., 2001 (Wharton et al., , 2004 Going et al., 2002) . As noted above, MCM7 is significantly overexpressed independently of the other MCM family members in multiple tumors, and additional functions for this family of molecules continue to be defined. For example, recent data demonstrate that p27 Kip1 can regulate G1/S progression and DNA replication through a direct interaction with MCM7 (Nallamshetty et al., 2005) . Additional MCM7 functions linking cell cycle regulation with DNA proliferation may be coopted by oncogenes such as Ras and MYCN (and C-MYC) .
Further in vitro and in vivo experiments are required to detail how deregulated MCM7 expression can contribute to tumorigenesis. In particular, experiments to test whether Ras-dependant transformation is altered by MCM7 modulation, as well as how MCM7 modifies transcription or other pathways to affect malignant transformation will further characterize the role of MCM7 in tumorigenesis.
Our data suggest that targeted overexpression of MCM7 in epidermal cells results in increased susceptibility to DMBA/TPA-induced tumorigenesis and malignant conversion. The MCM7 gene is transcriptionally regulated by E2F as well as by known oncogenes (C-Myc and N-MYC) and is known to interact with Rb and other cell cycle regulatory proteins. Clearly, the highly conserved MCM genes (MCM2-7), while essential components of the DNA replication-licensing factor, participate in additional critical cellular pathways. Additional in vivo and in vitro studies will elucidate those pathways contributing to tumorigenesis.
Materials and methods

Mouse models
To generate the K14.MCM7 mouse model, the MCM7 coding sequence was amplified from the human MCM7 cDNA (gift from Dr Tohru Kiyono, Nagaya University, Japan) with primers that added SnaB-I (5 0 ) and Xba-I (3 0 ) restriction sites. This fragment was then subcloned into the previously described pB3-R3 K14 expression vector (Waikel et al., 2001) . The K14.MCM7 construct was microinjected into fertilized oocytes of C57BL/6 mice by the Baylor College of Medicine Transgenic Mouse Core Facility. K14.MCM7 mice were identified by PCR analysis of isolated tail DNA using construct-specific oligonucleotides.
Chemical carcinogenesis protocol
Three-week-old mice were treated with 20 mg of DMBA (Sigma) dissolved in 200 ml of acetone applied topically to shaved back skin (20 mice in each group). One week following DMBA initiation, mice were treated with 5 mg of TPA (Sigma) dissolved in 200 ml of acetone applied topically to the back skin weekly for 50 weeks. Mice were monitored for tumor development and suspected conversion to SCC. Animals were killed when animals exhibited failing health or suspected carcinomas were B1 cm in diameter. Tumors were examined histologically to confirm malignancy. Malignant conversion rate was calculated as the ratio of total carcinomas per total papillomas. Differences between the control and K14.MCM7 mouse cohorts were evaluated using the two-sided unpaired ttest and Fisher -exact test.
RT-PCR analysis
Total RNA was isolated from either neonatal whole skin or tumors using Trizol Reagent (Invitrogen, Carlsbad, CA, USA). cDNA was prepared by reverse transcription of 1 mg total RNA. PCR amplification with Taq polymerase was performed as follows: 951C for 5 min then 30 cycles of 951C for 30 s, 601C for 30 s and 721C for 90 s. Primers specific for the human cDNA, which amplify a 145 bp fragment of MCM7 from bp position 534-679, were used to detect the transgene (5 0 GTGGCCACTTACACTTGTGACCAG) and (3 0 AGCCC CGTGTCTGCAGATACAGC).
Histological analysis
Skin sections for histological analysis were collected and fixed in 10% formalin-neutral buffer (NBF). Samples were then embedded in paraffin, sectioned and stained with hematoxylin and eosin. Minichromosomal maintenance protein 7 immunohistochemistry was performed as previously described (Shohet et al., 2002) .
Ras gene mutation analysis Formalin-fixed paraffin-embedded tumors were deparaffanized in xylene before DNA extraction. PCR analysis was performed using primers c-Ras-F 5 0 -ggggcaggagctcctggattgg cagccgct-3 0 and c-Ras-R: 5 0 -cctgtactgatggatgtcctcgaaggactt-3 0 for H-ras, Kras-1-FW: 5 0 -ttattgtaaggcctgctgaa-3 0 and Kras-1-RV: 5 0 -gcggcgttacctctatcgta-3 0 for codon 12 of K-ras, and Kras-2-FW: 5 0 -ttctcaggactcctacagga-3 0 and Kras-2-RV: 5 0 -acccacctataatggtgaat-3 0 for codon 61 of K-ras.
DNA ploidy
Five 50 mm sections of formalin-fixed paraffin-embedded tumors were deparaffinized in xylene, and rehydrated. To dissociate the cells, the samples were stirred in 5% trypsin for 2 h at 371C. After dissociation, the cells were fixed in cold ethanol and resuspended in 50 mg/ml Propidium Iodide. Flow cytometry was performed using a Beckman-Coulter Epics XL-MCL and data were analysed using the Modfit 3.0 programt (Verity Software House, Topsham, ME, USA).
Abbreviations K14, keratin 14; SCC, squamous cell carcinoma; DMBA, dimethylbenz [a] anthracene; TPA, 12-ortho-tetradecanoylphorbol-13-acetate; HNSCC, head and neck squamous cell carcinoma|MCM7, mimichromosomal maintenance protein 7 (cdc47).
